66 results
424B3
NBSE
NeuBase Therapeutics Inc
7 Jul 21
Prospectus supplement
5:16pm
acids (traditionally thought of as single-stranded DNA molecules) which bind to defective RNA targets in cells and inhibit their ability to form … targets comprised of secondary structures such as hairpins (double stranded RNA targets which are folded upon themselves). This allows us to potentially
8-K
EX-99.2
NBSE
NeuBase Therapeutics Inc
8 Jun 21
Regulation FD Disclosure
2:01pm
Targets Preclinical IND Clinical Myotonic Dystrophy (DM1) CTG Repeats in DMPK Causing Splice Dysfunction and Haploinsufficiency Oncology Point … growth inhibition in vivo High - value oncology targets previously considered “undruggable” Four months from inception to proof - of - principle 1
8-K
EX-99.2
ia8w18
14 Mar 22
Regulation FD Disclosure
6:07am
8-K
EX-99.1
r57crog3 vk58o4
16 Dec 20
Regulation FD Disclosure
9:00am
8-K
EX-99.2
77yzp6e09q14qc
22 May 23
Regulation FD Disclosure
7:00am
424B3
trt2fevj1hlu3tk qfv
23 Sep 19
Prospectus supplement
5:05pm
8-K
EX-99.1
28pf2lf6y6g s6ry2e
8 Jun 21
Regulation FD Disclosure
2:01pm
8-K
EX-99.2
nr7skzq
31 Mar 20
NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform
9:10am
8-K/A
EX-99.1
ndn0w 9i7nu5k7w8k
3 Apr 20
Financial Statements and Exhibits
5:10pm
424B5
qtgscdw86 r7j
27 Aug 21
Prospectus supplement for primary offering
5:21pm
424B5
7l3xkv2fl
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
dgf 12hzmlpmhf
21 Apr 21
Prospectus supplement for primary offering
4:03pm
425
EX-99.2
0j3m mtcbdh
3 Jan 19
Business combination disclosure
5:28pm
8-K
EX-99.2
fcnajogl
3 Jan 19
Entry into a Material Definitive Agreement
5:29pm